$ALC News

Last published 1d ago

1d agoALCInnovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 GrowthBusiness WireGENEVA--(BUSINESS WIRE)--Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
1d agoALCInnovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 GrowthBusiness WireGENEVA--(BUSINESS WIRE)--Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
3w agoALCAlcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2Business WireExpands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease Alcon's established presence and
3w agoALCFDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking EyesBusiness WireOne drop works to significantly reduce redness, with results lasting up to 12 hours1 Lasts up to 50% longer than Lumify1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be available in
1mo agoALCIntroducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom ReliefBusiness WireFormulated with hyaluronic acid, Systane® PRO PRESERVATIVE-FREE instantly hydrates dry eyes1 Systane® PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of
2mo agoALCAlcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise ControlBusiness WireFeatures industry-leading red reflex for stable, consistent visualization and Color Tunable Illumination for improved surgical precision1,2,*,† Latest addition to the UNITY platform that allows for modular upgrades
2mo agoALCAlcon Prices EUR 500 Million Senior Notes OfferingBusiness WireAlcon Inc. (SIX/NYSE:ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 3.875% senior notes due 2033 (the "Notes"). The Notes will be
3mo agoALCNew Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 GrowthBusiness WireSecond-quarter 2026 sales of $2.8 billion, up 8% on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025 Returned $538 million to shareholders through dividends and share repurchases on a
4mo agoRXST ALCAlcon and RxSight Announce Collaboration to Develop Adjustable PCIOLsGlobeNewswireNon-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class platform
4mo agoALC RXSTAlcon and RxSight Announce Collaboration to Develop Adjustable PCIOLsBusiness WireNon-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first-in-class
5mo agoALCApproval of Fluorescite, Nda #021980 (Labeling)FDA Approved DrugsApproval Date: 06/10/2026; Drug Name: Fluorescite, Nda #021980; Active Ingredients: FLUORESCEIN SODIUM; Company: Alcon Labs Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021980
6mo agoALCAlcon First Quarter 2026 Earnings CallALCON INCEarnings Call TranscriptsGreetings. Welcome to Alcon's first quarter 2026 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone today should require op
6mo agoALCNew Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr BuildsBusiness WireFirst-quarter 2026 sales of $2.7 billion, up 10% on a reported basis, or up 6% constant currency1 (cc), versus first-quarter 2025 First-quarter 2026 diluted EPS of $0.39; core diluted EPS2 of $0.85 Dividend of
6mo agoALCAlcon Announces Results of 2026 Annual General MeetingBusiness WireShareholders approve all agenda items presented R. Scott Herren elected as new independent member of the Board 2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes Alcon
7mo agoALCSystane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in CanadaBusiness WireNew partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game. This season, Alcon, the global leader in eye care dedicated
7mo agoALCAlcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026Business WireTruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across pupil sizes and
7mo agoALCAlcon Publishes Agenda for 2026 Annual General MeetingBusiness WireAlcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon
8mo agoALC LNSRAlcon and LENSAR, Inc. Agree to Terminate Merger AgreementBusiness WireAlcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies'
8mo agoALCAlcon Surpasses 175 Million IOLs Implanted GloballyBusiness WireMilestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom from
8mo agoALCAlcon Fourth Quarter 2025 Earnings CallALCON INCEarnings Call TranscriptsWelcome to Alcom's fourth quarter 2025 earnings conference call. Yesterday, we issued our press release, interim financial report, and earnings presentation. We also published our annual report on Form 20F. All these doc
8mo agoALCAlcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate SalesBusiness WireFourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated
8mo agoALCAlcon Launches TOTAL30 Multifocal for Astigmatism, the World's Only Monthly Multifocal Toric Contact Lens with Water Gradient TechnologyBusiness WireProvides excellent end of day comfort even on day 30,^ helping patients stay in contact lenses† comfortably1 Designed for aging eyes, the Water Gradient Material offers 3x greater surface lubricity* and at
9mo agoALCAlcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week FreshBusiness WirePRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal
9mo agoALCAlcon Completes $750 Million Share Repurchase ProgramBusiness WireAlcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate,
10mo agoALC STAAAlcon Terminates Agreement to Acquire STAAR SurgicalBusiness WireAd hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company
10mo agoALCAlcon to Present at 2026 Annual J.P. Morgan Healthcare ConferenceBusiness WireAlcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at
10mo agoALC STAABroadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to AlconBusiness WireUrges Board to Allow Shareholders to Have Their Final Say on This Ill-Conceived Transaction Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of
10mo agoALC STAAAlcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of StockholdersBusiness WireSTAAR Special Meeting of Stockholders Adjourned to January 6, 2026 STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE:ALC) has
10mo agoSTAA ALCDefender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.PR NewswireDefender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning...
10mo agoALC STAABroadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction FailsBusiness WireExpresses Confidence in STAAR's Future and the Opportunity for Significant Value Creation Believes STAAR is Worth at Least $50 Per Share If the Company Is Run in Best Interest of Shareholders Broadwood Partners, L.P.
10mo agoALC STAASTAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder ValueBusiness WireBroadwood Has Consistently Misled STAAR Stockholders About Takeover Interest in STAAR In Order to Derail the Alcon Merger STAAR Urges Stockholders to Vote "FOR" the Alcon Transaction on WHITE Proxy Card TODAY STAAR
11mo agoALC STAAYunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone TrajectoryBusiness WireYunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA),
11mo agoALC STAAIndependent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon TransactionBusiness WireIncreased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer®
11mo agoALC STAABroadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to AlconBusiness WireISS Says It Would Not Be "Unreasonable for a Shareholder to Remain Opposed" to the Deal Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom
11mo agoALC STAALeading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon MergerBusiness WireSTAAR Urges Stockholders to Vote "FOR" Alcon Merger on the WHITE Proxy Card TODAY STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer®
11mo agoALC STAABroadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to AlconBusiness WireContends STAAR's Process Was Ineffective in Establishing Competitive Auction and Securing Maximum Value for Shareholders Argues Board's Procedural Credibility Is "Remarkably Threadbare" Broadwood Continues to Urge
11mo agoALCAlcon Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
11mo agoALC STAASTAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop ProcessBusiness WireActivist Investors Have Twisted Facts Regarding STAAR's Engagement with a Potentially Interested Party During Go-Shop Process The Potentially Interested Party Reached Out on Day 21 of 30-Day Go-Shop Process and Refused
11mo agoALC STAABroadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to AlconBusiness WireEncouraged that at Least One Member of STAAR's Board Recognizes the Flaws of the Sale Process and that the Go-Shop Process was Performative Questions Completeness of Disclosures Given Critical Omission of Inbound
11mo agoALC STAAYunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised OfferBusiness WireBelieves STAAR's Sale Process Was Structured to Seal the Alcon Deal, Not to Maximize Value for Shareholders The Company Is Not Ripe for Sale at This Time Continues to Urge STAAR Shareholders to Vote "AGAINST" the
11mo agoALC STAABroadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR SurgicalBusiness WireNotes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder Value New Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's
11mo agoALC STAAAlcon Announces Amended Merger Agreement with STAAR SurgicalBusiness WireAgreement follows discussions with STAAR stockholders and the closure of STAAR's "go-shop" period New terms include an increase in acquisition price and reductions in payments to executives Alcon urges STAAR
11mo agoALC STAABroadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop ProcessBusiness WireBelieves Belated Go-Shop Process Fails to Cure Fundamental Flaws in the Transaction's Process, Timing, and Price Expresses Disappointment that the Self-Interested and Conflicted Board Members Continue to Press Forward
11mo agoALC STAABroadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote "AGAINST" Sale to AlconBusiness WireEgan-Jones Takes No Comfort From Perfunctory Go-Shop Process and Says Concerns Regarding Objectivity and Fairness Remain the Same Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced
11mo agoALC STAASTAAR Surgical Announces Expiration of Go-Shop PeriodBusiness WireNo Competing Acquisition Proposals Received Results of Go-Shop Process Validate the Effectiveness of the STAAR Board's Process Now is the Right Time to Sell the Business and Alcon is the Right Buyer STAAR Surgical
11mo agoALC STAABroadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three DirectorsBusiness WirePursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process Broadwood Seeks to Remove the Directors Most Responsible for the Flawed Sale Process: Board Chair Elizabeth Yeu, CEO
11mo agoALCAlcon Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
1y agoALCAlcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum BuildsBusiness WireThird-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6
1y agoALC STAABroadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop ProcessBusiness WireBelieves New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full
1y agoALC STAASTAAR Surgical Announces Amendments to Alcon Merger AgreementBusiness Wire30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder Alcon Waives All